Background
==========

Infertility refers to the inability of a couple to conceive after 12 months of regular unprotected sexual intercourse; it affects 10--15% of couples \[[@b1-medscimonit-24-1379]\]. Male factor infertility is implicated in half of these couples \[[@b2-medscimonit-24-1379],[@b3-medscimonit-24-1379]\]. The most severe form of male infertility, azoospermia, is present in 1% of males in the general population and accounts for 10--15% of male infertility. Azoospermia is divided into obstructive azoospermia (OA) and non-obstructive azoospermia (NOA). OA is due to a blockage anywhere along the path of sperm transit: efferent ducts to the epididymis, then vas deferens, followed by ejaculatory duct, and finally the urethra, before exiting from the urethral meatus. Depending on the level of obstruction, some men can undergo microsurgical reconstruction or ejaculatory duct resection, while others require sperm retrieval via the testicles or epididymis. NOA is due to defective spermatogenesis and can be classified as hypospermatogenesis (HS), maturation arrest (MA), or Sertoli cell only syndrome (SCOS) \[[@b4-medscimonit-24-1379]\]. Defective spermatogenesis may be due to genetic abnormalities such as Y chromosome microdeletions or karyotype abnormalities in 15% of NOA patients, but is largely idiopathic \[[@b5-medscimonit-24-1379]\]. Thus, men with NOA have fewer therapeutic options and reproduction relies on successful surgical sperm retrieval.

Micro-TESE is considered the criterion standard for sperm retrieval among NOA patients with the highest sperm retrieval rates while minimizing tissue loss \[[@b6-medscimonit-24-1379]--[@b8-medscimonit-24-1379]\]. However, sperm extracted from the testis have unique characteristics. The sperm obtained via retrieval in men with NOA are often immature and have not acquired proper motility. Therefore, they are not all viable and embryologists must rely on signs of potential success such as subtle twitching of the tails. Moreover, previous studies have identified a greater frequency of cytogenetically abnormal spermatozoa from men with NOA, despite their normal somatic karyotype \[[@b9-medscimonit-24-1379],[@b10-medscimonit-24-1379]\]. Vozdova et al. \[[@b11-medscimonit-24-1379]\] also demonstrated that testicular sperm samples of NOA patients show a higher incidence of numerical chromosomal abnormalities compared with ejaculated sperm of control donors as shown by multi-color fluorescence *in situ* hybridization. Although most relevant studies suggest that the rate of successful fertilization utilizing cryopreserved-thawed testicular spermatozoa is similar to that of fresh sperm, the freezing and thawing process can further damage sperm \[[@b12-medscimonit-24-1379],[@b13-medscimonit-24-1379]\], and this can limit the number of viable sperm amenable to assisted reproduction technology. When available, use of fresh testicular sperm among NOA patients is preferred.

Oocyte cryopreservation is a viable option for fertility preservation among women undergoing cancer therapy and those with premature ovarian insufficiency \[[@b14-medscimonit-24-1379],[@b15-medscimonit-24-1379]\]. Since human oocyte vitrification was first reported, this technology has evolved and is widely used clinically \[[@b16-medscimonit-24-1379],[@b17-medscimonit-24-1379]\]. Oocyte cryopreservation has also become an important alternative to cryopreserved embryos for *in vitro* fertilization (IVF). More recent studies have demonstrated that vitrification of oocytes does not have a negative effect on oocyte physiology or the chromosomal status of the embryos derived \[[@b18-medscimonit-24-1379]--[@b21-medscimonit-24-1379]\]. Our reproductive center has been dedicated to the development of oocyte vitrification techniques and has achieved remarkable results.

In this study, we compared SRR among NOA patients stratified by the etiology of the NOA, and retrospectively compared fertilization and pregnancy outcomes of ICSI-ET cycles with fresh or frozen-thawed oocytes combined with testicular sperm derived from OA or NOA patients. We evaluated the feasibility of oocyte vitrification combined with micro-TESE.

Material and Methods
====================

Subjects and treatment protocol
-------------------------------

We retrospectively analyzed the medical records of NOA patients who underwent micro-TESE and OA patients who underwent TESA between December 2015 and February 2017 at the Department of Reproductive Medicine, Third Affiliated Hospital of Guangzhou Medical University, China. Azoospermia was confirmed by testing of at least 3 semen samples. All patients had a physical examination and assessment of sex hormones levels before surgical sperm retrieval. All 150 patients with NOA were assessed by a testicular volume clinical exam, serum studies (e.g., FSH, LH, and testosterone levels), and genetic studies (e.g., karyotyping and Y chromosome deletion analysis). We excluded patient with azoospermia secondary to testicular malignancy, any prior radiotherapy, and chemotherapy. The study protocol was approved by the Ethics Committee of the Third Affiliated Hospital of Guangzhou Medical University and all patients provided written informed consent before their micro-TESE and TESA.

Four groups were created based on the type of oocytes used (vitrified or fresh) and etiology of azoospermia (NOA, OA, or failure to ejaculate). Group 1 consisted of 70 NOA patients with fresh sperm obtained via micro-TESE. Those sperm underwent ICSI with vitrified and warmed oocytes. Group 2 was established to reduce the bias of only utilizing micro-TESE obtained sperm from NOA men with the vitrified oocytes. There were 10 men who were unable to provide an ejaculated sample and refused to accept TESA at the time of the oocyte retrieval. The oocytes were frozen. If the men still were unable to provide an ejaculated sample at a later time, they underwent testicular biopsy and ICSI-ET was performed with the sperm and the vitrified-then-warmed oocytes. Group 3 consisted of 80 NOA patients who underwent micro-TESE on the same day of oocyte retrieval for ICSI. Group 4 utilized sperm retrieved from 174 OA males either by TESA or with fresh oocytes. All couples were enrolled for final analysis ([Figure 1](#f1-medscimonit-24-1379){ref-type="fig"}).

Micro-TESE and testicular sperm aspiration (TESA)
-------------------------------------------------

All surgical procedures of micro-TESE were performed according to the description of Schlegel and Li \[[@b22-medscimonit-24-1379]\] with some modifications. All the surgeries were performed by a single surgeon. Briefly, under epidural anesthesia, a mid-line scrotal incision was made on the median raphe of the scrotum. A transverse tunical incision was performed. Following bipolar hemostasis, the testicular parenchyma was directly examined under an operating microscope (Leika M525 F40, Germany) at ×25 magnification. Opaque and more dilated tubules were removed and immediately placed into a sperm buffer (Vitrolife, Sweden). Retrieved tubules were ground into suspensions by microscopic tweezers and examined under bright-field microscopy (Olympus CKX41, Japan) concomitantly during the surgical procedure. When spermatozoa were identified from the tubules, additional seminiferous tubules from this region of sperm production were retrieved. If the sperm were not found on one side of the testis, we would open the other side of the testis. For all NOA patients, we sent some testicular tissue for histological analysis. In TESA, the aspirations were usually carried out using a needle attached to a syringe. The needle was inserted through the scrotal skin into the testis. The needle was usually inserted into the anterolateral portion of the superior testicular pole at an oblique angle toward the medium and lower poles. The testicular parenchyma was aspirated by creating negative pressure, and the specimen was sent to the laboratory.

The extracted testicular tissue was placed in a Petri dish with 1 ml G-MOPS-Plus (Vitrolife, Sweden) supplemented with 10% human albumin serum (HSA; Vitrolife, Sweden) and minced into testicular cell suspensions. Sperm were isolated and selected for use in ICSI.

Vitrification and warming of oocytes
------------------------------------

The mature MII stage oocytes were placed in G-MOPS-plus (Vitrolife, Sweden) after rinsing and resting for 1 min. Oocytes were then placed in ES equilibrium solution (Kitazato Biophama, Japan) for 10 min. The oocytes first appeared to shrink, but then returned to their original size. The mature oocytes were transferred to the vitrification solution (VS solution), and then transferred to the frozen carrier and stored in liquid nitrogen. All procedures were performed at room temperature (\~25°C).

Warming was performed on the day of sperm retrieval via surgical procedure. Briefly, the carrier equipped with frozen oocytes was removed from the liquid nitrogen tank and quickly placed in a liquid containing WS1 solution (Kitazato Biophama, Japan) in a thawing dish. Oocytes were transferred to the WS2 (Kitazato Biophama, Japan) and WS3 (Kitazato Biophama, Japan) solutions at room temperature (\~25°C) for 3 min each. Then, oocytes were transferred into culture medium (SSM) and incubated for 3 h at 37°C (6% CO~2~ and 5% O~2~) before they were used for ICSI. Degenerated oocytes were removed from the Petri dishes.

Ovarian stimulation and ICSI
----------------------------

A single stimulation cycle was included for each group. The ovarian induction protocol was performed with the standard long protocol. The ovarian stimulation and oocyte retrieval procedure were conducted by ultrasound-guidance through the vagina, as well as embryo culture, as described in the literature \[[@b23-medscimonit-24-1379]\]. Subsequently, ICSI was performed as previously described \[[@b24-medscimonit-24-1379]\]. On day 1, at 16--18 h after insemination, all embryos were checked for fertilization. On day 2, all embryos in different groups were checked for cell number and fragmentation. On day 3, all embryos were checked for cell number, fragmentation, and cell symmetry, then embryos were scored according to the SART scoring system \[[@b25-medscimonit-24-1379]\]. Embryo transfer was performed on day 3 after oocyte retrieval. The best embryos were selected for transfer. The remainder of the embryos were followed for blastocyst formation and subsequently frozen. Pregnancy was confirmed by the rise of serum b-human chorionic gonadotropin (hCG) concentration 14 days after ET. Clinical pregnancy was defined as a visible sac in the fifth gestational week. The miscarriage rate was considered the loss of a clinical pregnancy per cycle before 20 completed weeks of gestation. This information was reported to our clinic after communication with the couples by our follow-up staff.

Statistical analysis
--------------------

All data was analyzed using the Statistical Package for the Social Sciences program (SPSS for Windows 16.0, SPSS Inc, USA). One-way ANOVA was used to assess the different outcomes of ICSI among the 4 groups. The data are expressed as the mean ±SEM. *P*-value \<0.05 was considered statistically significant in all analyses.

Results
=======

Patient characteristics
-----------------------

A total of 150NOA patients received micro-TESE treatment. Due to the differences in etiology and histopathology, we divided NOA patients into maturation arrest (MA), Sertoli cell only syndrome (SCOS), AZFc deletions, cryptorchidism, and Klinefelter syndrome (KS). For a variety of reasons, 174 OA and 10 failure-to-ejaculate patients received TESA treatment. Pre-operatively, sex hormones were checked for all the patients. [Table 1](#t1-medscimonit-24-1379){ref-type="table"} describes the pre-operative characteristics of patients in the different groups, including female age and endocrine lab results. There was a significant statistical difference in the FSH and testicular volume between OA and NOA patients. All the enrolled patients underwent micro-TESE or TESA, ICSI treatment, and embryo transfer.

Micro-TESE and success rate of sperm retrieval
----------------------------------------------

The overall SRR for NOA patients was 48.7% (73/150) ([Table 2](#t2-medscimonit-24-1379){ref-type="table"}.). SRR was highest for those with a histological diagnosis of hypospermatogenesis (80.5%) and lowest in SCOS (25%), which agrees with results in the literature. Motile spermatozoa were successfully obtained in all 174 patients (100%) with OA.

Outcome of ICSI-ET cycles in NOA and OA
---------------------------------------

In group 1, among the 70 NOA patients, sperm retrieval via micro-TESE was successful in 35 patients (50%).Vitrified-warmed oocytes were used on the day of micro-TESE. In group 2, 10 patients underwent testicular biopsy because of the inability to produce an ejaculated specimen. In group 3, 80 NOA patients received micro-TESE on the day of oocyte retrieval and 38 patients (47.5%) had successful sperm retrieval enabling subsequent ICSI. In group 4, testicular sperm were successfully obtained in all 174 patients (100%) with OA.

The outcome of ICSI-ET cycles is presented in [Table 3](#t3-medscimonit-24-1379){ref-type="table"}. Fertilization rates were similar among groups 1 to 4 (73.8%, 77.2%, 72.8%, and 73.6%, respectively). Implantation rates were 33.3%, 34.7%, 33.8%, and 37.5%, respectively. Clinical pregnancy rates were 51.4%, 60%, 52.6%, and 51.7%, respectively. There were no statistically significant differences between the different groups (*p*\>0.05). Concerning the embryo developmental competence, rate of quality embryos on day 3 were observed among embryos derived from vitrified and fresh oocytes. With respect to the vitrified warmed oocytes (group 1 and 2), quality embryo rates were significantly lower in group 1 (29.0±8.3) compared to group 2 (43.1±10.9) (*p*\<0.05). Similarly, D3 available embryo rates were lower in group 1 (31.3±9.0) compared to group 2 (46.5±8.7) (*p*\<0.01). With respect to fresh oocytes (groups 3 and 4), quality embryo rates were lower in group 3 (30.5±8.7) when compared to group 4 (47.5±13.6), (*p*\<0.01). D3 available embryos rate were also lower in group 3 (32.6±12.2) when compared to group 4 (47.7±13.4) (*p*\<0.01).

Discussion
==========

It is established that TESE is the recommended method for sperm retrieval in men with testicular failure. Due to the fact that individual seminiferous tubules can be seen under the microscope, several authors have proposed that micro-TESE is a better method for sperm retrieval than conventional TESE \[[@b26-medscimonit-24-1379]--[@b28-medscimonit-24-1379]\]. However, those studies did not stratify SRR by the different etiologies of NOA. In this study, we analyzed our SRR using micro-TESE among 150 patients with NOA. Our SRR range, from 25% to 63%, was comparable to that in the reported literature \[[@b29-medscimonit-24-1379]--[@b31-medscimonit-24-1379]\]. Our study also demonstrates that the etiology of NOA is predictive of the corresponding SRR. While the overall SRR for the 150 NOA patients was 48.7%, it was least successful in Sertoli cell only syndrome (25%), followed by Klinefelter syndrome (28.6%), maturation arrest (31.6%), and AZFc deletion (70%), and was most successful in hypospermatogenesis (80.5%).

The development of sperm cryopreservation provides a guarantee to the preservation of male fertility. Testicular sperm can also be obtained and frozen before the initiation of controlled ovarian hyperstimulation for delayed ICSI. Karacan \[[@b32-medscimonit-24-1379]\] reported that neither the timing of TESE (on the day of or the day before oocyte retrieval) nor the use of frozen-thawed testicular sperm affects the outcome of ICSI-ET cycle when motile spermatozoa are obtained in azoospermic men. However, for NOA patients undergoing micro-TESE, the amount of sperm retrieved is often small. Traditional freezing techniques do not guarantee the quantity and quality of thawed spermatozoa. Various methods of cryopreservation for very low numbers of spermatozoa, such as ICSI pipettes \[[@b33-medscimonit-24-1379]\], cryoloop \[[@b34-medscimonit-24-1379]\], LSL micro-straws \[[@b35-medscimonit-24-1379]\], agarose capsules \[[@b36-medscimonit-24-1379]\], and hyaluronan microcapsules \[[@b37-medscimonit-24-1379]\] have been reported. However, each of these methods has its own problem. It is often difficult to find available sperm immediately due to the spermatozoa quantity being very low compared with the number of embryos needed. In addition, recovery rate is also a limiting factor. Therefore, selection of fresh sperm for fertilization is still the best option. However, new problems arise from this: in particular, when sperm is unable to be obtained by micro-TESE, the risk arises from necessity of canceling the oocyte harvest. Now that vitrification has proven to be a promising and popular alternative to cryopreserved oocytes in the field of assisted reproduction, our ideas could evolve accordingly. In this study, we explored the feasibility and clinical outcomes of vitrified oocyte cryopreservation combined with micro-TESE.

The outcomes of ICSI-ET fertilization rates and implantation rates were similar between the micro-TESE patients and TESA patients (group 1 and 3 *vs.* group 2 and 3). However, quality embryos rates and D3 available embryos rates in TESA patients were higher than in micro-TESE patients (group 1 *vs.* group 2). Our results demonstrate that the testicular sperm of males with normal sperm production may have better development potential than testicular sperm from men with NOA. Several studies have indicated that NOA patients produced increased numbers of cytogenetically abnormal testicular spermatozoa despite their normal somatic karyotype, and were at increased risk of producing aneuploid gametes and transmitting chromosome aneuploidy to the zygote \[[@b11-medscimonit-24-1379],[@b12-medscimonit-24-1379],[@b38-medscimonit-24-1379]\]. These factors may lead to a reduced developmental potential of embryos derived from sperm of NOA males than in embryos derived from sperm of men with normal spermatogenesis. However, selecting the best embryos which result in a pregnancy is a challenge across all IVF laboratories. In our study, when choosing the best embryos for implantation according to the SART scoring system, clinical pregnancies (51.4%, 60%, 52.6%, and 51.7%) and miscarriage rates (11.1%, 16.7%, 10.0%, and 13.3%) were not statistically different among the groups.

Since the first development of oocyte vitrification, it is now possible to vitrify and warm unfertilized eggs at near maximal efficiency, resulting in high cell survival rates \[[@b39-medscimonit-24-1379]\]. Many studies have suggested that vitrified oocytes preserve the potential to be fertilized and to develop into high-quality blastocysts. In addition, the success rates of ICSI using vitrified oocytes are similar to those obtained with fresh insemination with regards to fertilization, embryo developmental competence, pregnancy rates, and live birth \[[@b40-medscimonit-24-1379]--[@b44-medscimonit-24-1379]\]. Forman et al. \[[@b19-medscimonit-24-1379]\] also demonstrated that oocyte vitrification does not increase the rate of aneuploidy or diminish the implantation potential of viable blastocysts. With the birth of healthy infants resulting from vitrified oocytes, this efficient and safe technique could become more widely available to women who are seeking fertility preservation \[[@b45-medscimonit-24-1379]--[@b47-medscimonit-24-1379]\]. In our study, we undertook a retrospective analysis of the data on success in combining vitrified oocytes with sperm obtained via micro-TESE of NOA males. In the group of vitrified oocytes, we observed a total survival rate of 91.5% after warming. Our results are similar to those reported in open vitrification system studies and a recent systematic review \[[@b48-medscimonit-24-1379],[@b49-medscimonit-24-1379]\]. These data further illustrate the stability and feasibility of oocyte vitrification and the value of clinical applications.

Moreover, our study suggests that fertilization rate, implantation rate, and clinical pregnancies are not affected by the oocyte vitrification procedure between the 2 groups of NOA patients (group 1 and group 3). Similar to embryos derived from fresh oocytes, vitrified oocytes preserve the potential to be fertilized and to develop into high-quality blastocysts. Our results are also comparable to Forman's report, which was a paired randomized study \[[@b21-medscimonit-24-1379]\]. At present, due to the promising results and the safety of the oocyte vitrification as demonstrated by successful fertilization, embryo developmental competence, pregnancy rates, and live birth numbers, vitrification is an efficient, harmless, and safe technique that can be widened in use and proposed to women who are seeking fertility preservation for social reasons \[[@b40-medscimonit-24-1379],[@b50-medscimonit-24-1379],[@b51-medscimonit-24-1379]\]. Our results support the use of oocyte vitrification as a feasible option for couples when the male has NOA and requires surgical sperm retrieval. Limitations to this study include the lack of live-birth outcomes and the necessity for more clinical samples, such as in group 2. However, fertilization rates, embryo developmental competence, and clinical pregnancy rates are all well recognized end points.

Conclusions
===========

In this study, our results confirmed the hypothesis that ICSI outcomes utilizing vitrified oocytes and spermatozoa acquired from micro-TESE demonstrated similar fertilization rates, implantation rates, and clinical pregnancies compared with ICSI utilizing fresh oocytes. However, the testicular sperm of NOA patients leads to lower embryo developmental competence compared to that of OA patients. Therefore, the use of oocyte vitrification is a feasible management option for couples when the male presents with NOA and requires surgical sperm retrieval.
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###### 

Baseline characteristics of different groups.

  Characteristics           Group 1 micro-TESE on vitrified warmed   Group 2 TESA on vitrified warmed   p-Value                                                      Group 3 micro-TESE on oocytes retrieval   Group 4 TESA on oocytes retrieval   p-Value
  ------------------------- ---------------------------------------- ---------------------------------- ------------------------------------------------------------ ----------------------------------------- ----------------------------------- ------------------------------------------------------------
  Male age                  31.2±3.3                                 32.9±3.8                           0.783                                                        31.7±3.6                                  31.9±3.9                            0.653
  Female age                27.8±3.2                                 32.8±4.6                           0.674                                                        29.4±3.3                                  28.6±3.5                            0.573
  FSH (mIU/ml)              15.9±5.1                                 5.4±1.4                            \<.000[\*](#tfn1-medscimonit-24-1379){ref-type="table-fn"}   18.0±4.7                                  5.2±1.2                             \<.000[\*](#tfn1-medscimonit-24-1379){ref-type="table-fn"}
  LH (mIU/ml)               5.1±1.5                                  4.7±1.1                            0.937                                                        4.9±1.4                                   4.9±1.3                             1.000
  T (ng/ml)                 7.3±3.7                                  13.2±8.7                           0.201                                                        6.8±3.8                                   12.4±5.2                            \<.000[\*](#tfn1-medscimonit-24-1379){ref-type="table-fn"}
  PRL (ng/ml)               9.1±4.4                                  7.5±2.0                            0.935                                                        7.8±2.7                                   8.8±4.4                             0.283
  Testicular volume (ml)    5.9±2.5                                  12.0±1.6                           \<.000[\*](#tfn1-medscimonit-24-1379){ref-type="table-fn"}   6.2±2.9                                   12.2±1.7                            \<.000[\*](#tfn1-medscimonit-24-1379){ref-type="table-fn"}
  KS (47,XXY)               6                                        --                                                                                              8                                         --                                  NC
  Cryptorchidism            7                                                                                                                                        5                                         --                                  NC
  AZFc deletion             5                                                                                                                                        5                                         --                                  NC
  Histopathology                                                                                                                                                                                                                                   
  Maturation arrest         24                                       --                                                                                              33                                        --                                  NC
  Hypospermatogenesis       23                                       --                                                                                              18                                        --                                  NC
  SCOS                      6                                        --                                                                                              10                                        --                                  NC
  Obstructive azoospermia                                                                                                                                                                                      174                                 NC
  Ejaculation difficulty                                             10                                                                                                                                        NC                                  

Statistically significant.

###### 

The sperm retrieval rate (SRR) using Micro-TESE.

  Classification         Micro-TESE   Obtained sperm   SRR(%)
  ---------------------- ------------ ---------------- --------
  Histopathology         114          55               48.2
   Maturation arrest     57           18               31.6
   Hypospermatogenesis   41           33               80.5
   SCOS                  16           4                25.0
  KS (47,XXY)            14           4                28.6
  Cryptorchidism         12           8                66.7
  AZFc deletion          10           7                70.0
  Total                  150          73               48.7

###### 

Outcome of ICSI-ET cycles in different groups.

  Variable                   Group 1        Group 2       P-value                                                     Group 3        Group 4         P-value
  -------------------------- -------------- ------------- ----------------------------------------------------------- -------------- --------------- ------------------------------------------------------------
  Number of cycles           35             10                                                                        38             174             
  Number of oocytes          11.1±2.8       11.4±2.8      1.000                                                       12.2±3.5       11.5±3.1        0.838
  Oocyte survival rate (%)   91.2±3.6       92.6±3.8      0.290                                                       --             --              --
  Number of Injected         8.8±2.5        9.2±1.8       0.996                                                       9.1±2.2        8.9±2.2         1.000
  Fertilization rate (%)     73.8±8.9       77.2±10.6     0.935                                                       72.8±7.4       73.6±8.0        0.990
  Transferred embryos        1.5±0.5        1.5±0.5       0.807                                                       1.6±0.5        1.5±0.5         0.878
  Quality embryos rate (%)   29.0±8.3       43.1±10.9     0.015[\*](#tfn2-medscimonit-24-1379){ref-type="table-fn"}   30.5±8.7       47.5±13.6       \<.000[\*](#tfn2-medscimonit-24-1379){ref-type="table-fn"}
  D3 available embryos       31.3±9.0       46.5±8.7      0.001[\*](#tfn2-medscimonit-24-1379){ref-type="table-fn"}   32.6±12.2      47.7±13.4       \<.000[\*](#tfn2-medscimonit-24-1379){ref-type="table-fn"}
  Implantation rate (%)      33.3±14.3      34.7±10.3     1.000                                                       33.8±12.4      37.5±12.1       0.461
  Clinical pregnancies (%)   51.4 (18/35)   60.0 (6/10)                                                               52.6 (20/38)   51.7 (90/174)   NC
  Miscarriage rates (%)      11.1 (2/18)    16.7 (1/6)                                                                10.0 (2/20)    13.3 (12/90)    NC

Statistically significant.
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